SC rejects plea for CBI probe into cough syrup deaths
- byDoctor News Daily Team
- 11 October, 2025
- 0 Comments
- 0 Mins
In a swift legal action, the Supreme Court of India dismissed a Public Interest Litigation (PIL) demanding an inquiry and systemic reform in drug safety mechanisms following the tragic deaths of children in Madhya Pradesh and Rajasthan, allegedly due to the consumption of toxic cough syrups. The PIL, filed by lawyer Vishal Tiwari, sought urgent intervention into the matter. A bench comprising Chief Justice B R Gavai and Justices Ujjal Bhuyan and K Vinod Chandran dismissed the PIL after Solicitor General Tushar Mehta objected to it. As per PTI, the top law officer said the petitioner reads the newspaper and rushes to the court. The bench, which was initially of the view that the notice should be issued, later dismissed it. Mehta said he was not appearing for any state at the moment but the seriousness with which states like Tamil Nadu and Madhya Pradesh are taking actions cannot be undermined. Moreover, there are proper law enforcement mechanisms in states, he added. The bench asked Tiwari as to how many PILs he has filed so far in the top court and on being told that he has moved eight to 10 such pleas so far, the bench dismissed the instant petition. "Dismissed," the CJI said. The PIL claimed that laboratory tests conducted by the Madhya Pradesh government confirmed that Diethylene Glycol (DEG)—a toxic industrial solvent prohibited for pharmaceutical use—was found in 'Coldrif Cough Syrup', manufactured by Tamil Nadu's Sresan Pharma Pvt. Ltd. “Despite the catastrophic findings, the Union Government and the Central Drugs Standard Control Organisation (CDSCO) allegedly failed to issue an immediate nationwide recall or ban, permitting the continued circulation of potentially poisonous medicines across States,” the plea stated. “This is not a tragedy of chance but of negligence, apathy, and regulatory failure -- an institutional rot that allows counterfeit and adulterated drugs to enter the public market unchecked,” the PIL stated.
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
Tags:
Recent News
Pfizer files lawsuit against Metsera, its Director...
- 02 November, 2025
Health Ministry achieves 3 Guinness World Records...
- 02 November, 2025
Roche gets CE mark for Elecsys Dengue Ag test to d...
- 02 November, 2025
Aadhaar authentication voluntary for NBE exams, cl...
- 02 November, 2025
Daily Newsletter
Get all the top stories from Blogs to keep track.
0 Comments
Post a comment
No comments yet. Be the first to comment!